View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
  2. Company News
August 29, 2018

GENFIT completes enrolment in Phase lla trial of elafibranor for PBC

GENFIT has completed patient enrolment in a Phase lla trial to investigate the efficacy and safety of elafibranor for the treatment of patients with Primary Biliary Cholangitis (PBC) and inadequate response to ursodeoxycholic acid.

GENFIT has completed patient enrolment in a Phase lla trial to investigate the efficacy and safety of elafibranor for the treatment of patients with Primary Biliary Cholangitis (PBC) and inadequate response to ursodeoxycholic acid.

The multicentre, double-blind, randomised, placebo-controlled trial enrolled 45 patients, some of whom have already completed the trial’s 12-week treatment period.

The trial includes three arms to provide 80mg and 120mg of elafibranor, and placebo. Each arm of the study comprises 15 patients.

It is being conducted at several clinical centres in the US and Europe.

The trial’s primary goal is to determine the effect of daily oral administration of elafibranor on serum alkaline phosphatase (ALP) in the enrolled patients.

Its secondary endpoints comprise safety and tolerability of elafibranor, particularly on pruritus, and quality of life.

“This attribute, along with what PPAR agonists have demonstrated on ALP reduction, provides a strong rationale for elafibranor in PBC.”

Top line data from the trial is scheduled to be unveiled by the end of this year.

Sophie Mégnien, Chief Medical Officer of GENFIT, added: “Elafibranor, a dual PPAR alpha and delta agonist, is an attractive candidate for PBC patients due to its impact on lowering alkaline phosphatase levels, as shown consistently in previous clinical studies, on other populations.

“This attribute, along with what PPAR agonists have demonstrated on ALP reduction, provides a strong rationale for elafibranor in PBC.

“Recent clinical data has shown that PPAR alpha may also have a positive impact on pruritus, which further differentiates the dual mechanistic action of elafibranor to not only improve liver biochemistry (delta) but also alleviate pruritus (alpha) in this rare disease.”

PBC is a rare autoimmune disease that occurs due to the gradual damage of bile ducts in the liver, which could result in cirrhosis and even liver failure.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena